Enzyme Replacement Therapy Market Size Growth: From $13.42 Billion In 2026 To $19.28 Billion By 2030
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Enzyme Replacement Therapy Market Forecast: Value Set To Climb From $13.42 Billion To $19.28 Billion
The enzyme replacement therapy market has experienced robust expansion in recent years. Its value is anticipated to rise from $12.36 billion in 2025 to $13.43 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.6%. This past growth can be ascribed to factors such as the increasing incidence of lysosomal storage disorders, developments in recombinant DNA technology, heightened awareness regarding rare diseases, improved hospital infrastructure, and government efforts supporting treatments for rare conditions.
The enzyme replacement therapy market is projected to experience robust expansion over the coming years. This market is anticipated to reach $19.29 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. Factors contributing to this growth during the forecast period include the broadening scope of precision medicine, the creation of innovative enzyme formulations, a rise in the use of home infusion therapies, the incorporation of digital health solutions, and an increase in partnerships between biotechnology firms and research institutions. Key trends anticipated for the forecast period encompass individualized enzyme replacement therapies, the enlargement of programs for treating rare diseases, the advancement of extended-release enzyme formulations, the utilization of less invasive administration methods, and the incorporation of real-world data for optimizing therapeutic approaches.
Get A Free Sample Report With In-Depth Market Insights:
Enzyme Replacement Therapy Market Expansion Drivers: What’s Shaping Future Growth?
The growth of the enzyme replacement therapy (ERT) market is expected to be propelled by increasing healthcare expenditure. This expenditure refers to the total amount of money allocated to , related goods, and activities within a specific healthcare system or economy over a defined period. Healthcare expenditure is essential for enzyme replacement therapy (ERT) primarily due to the specialized and often costly nature of these treatments, specifically for research and development and clinical trials and testing. For instance, in June 2025, the US-based federal agency, Centers for Medicare & Medicaid Services (CMS), indicated that National Health Expenditure (NHE) saw a 7.5% increase to $4.9 trillion in 2023, amounting to $14,570 per person, and constituting 17.6% of Gross Domestic Product (GDP). Hospital expenditures climbed 10.4% to $1,519.7 billion in 2023, which was a faster expansion compared to the 3.2% growth in 2022. Therefore, the rising healthcare expenditures are a key factor driving the expansion of the enzyme replacement therapy (ERT) market.
Enzyme Replacement Therapy Market Segment Trends And Revenue Contributors
The enzyme replacement therapy market covered in this report is segmented –
1) By Enzyme Type: Agalsidase Alfa, Agalsidase Beta, Galsulfase, Other Enzyme Types
2) By Route Of Administration: Oral, Parenteral
3) By Application: Gaucher Disease, Pompe Disease, Fabry Disease, Other Applications
4) By End-Users: Hospitals, Infusion Centers, Other End-Users
Enzyme Replacement Therapy Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies in the enzyme replacement therapy (ERT) market are prioritizing innovative treatment products and seeking approval for Pompe disease therapies to address the significant unmet medical needs of patients with late-onset Pompe disease. Illustratively, a treatment for Pompe disease available in the European Union, which comprises Pombiliti (cipaglucosidase alfa) and Opfolda (miglustat), serves as an enzyme replacement therapy for adults with late-onset Pompe disease. As a specific example, in June 2023, Amicus Therapeutics, a US-based biotechnology company, announced the approval and launch of a novel Pompe disease therapy in the European Union. This initiative was undertaken to meet the unmet medical need for patients with late-onset Pompe disease, bolstered by clinical data, and driven by potential market opportunities and regulatory support. This therapy, consisting of Pombiliti (cipaglucosidase alfa) and Opfolda (miglustat), functions as an enzyme replacement therapy for adults with late-onset Pompe disease.
Enzyme Replacement Therapy Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the enzyme replacement therapy market are Biomarin Pharmaceutical Inc., Leadiant Biosciences Inc., Pfizer Inc., Sanofi S.A., AbbVie Inc., Alexion Pharmaceuticals Inc., Recordati Rare Diseases Inc., JCR Pharmaceuticals Co. Ltd., Horizon Pharma Public Limited Company, Protalix Biotherapeutics Ltd., Amicus Therapeutics Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Retrophin Inc., Abeona Therapeutics Inc., Orchard Therapeutics plc, Ultragenyx Pharmaceutical Inc.
View The Full Enzyme Replacement Therapy Market Report:
Enzyme Replacement Therapy Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the enzyme replacement therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global enzyme replacement therapy market report during the forecast period. The regions covered in the enzyme replacement therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
